Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CEMI's Cash to Debt is ranked higher than
94% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. CEMI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CEMI' s 10-Year Cash to Debt Range
Min: 0.02  Med: 25.32 Max: No Debt
Current: No Debt
Equity to Asset 0.80
CEMI's Equity to Asset is ranked higher than
79% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. CEMI: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
CEMI' s 10-Year Equity to Asset Range
Min: -2.07  Med: 0.58 Max: 0.86
Current: 0.8
-2.07
0.86
Interest Coverage No Debt
CEMI's Interest Coverage is ranked higher than
88% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. CEMI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CEMI' s 10-Year Interest Coverage Range
Min: 28.82  Med: 5085.80 Max: 9999.99
Current: No Debt
28.82
9999.99
F-Score: 1
Z-Score: 5.92
M-Score: -0.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -7.28
CEMI's Operating margin (%) is ranked lower than
56% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. CEMI: -7.28 )
Ranked among companies with meaningful Operating margin (%) only.
CEMI' s 10-Year Operating margin (%) Range
Min: -302.06  Med: -12.18 Max: 15.41
Current: -7.28
-302.06
15.41
Net-margin (%) -5.56
CEMI's Net-margin (%) is ranked lower than
54% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. CEMI: -5.56 )
Ranked among companies with meaningful Net-margin (%) only.
CEMI' s 10-Year Net-margin (%) Range
Min: -93.74  Med: -10.88 Max: 32.02
Current: -5.56
-93.74
32.02
ROE (%) -7.84
CEMI's ROE (%) is ranked lower than
54% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. CEMI: -7.84 )
Ranked among companies with meaningful ROE (%) only.
CEMI' s 10-Year ROE (%) Range
Min: -14522.12  Med: -1.29 Max: 67.84
Current: -7.84
-14522.12
67.84
ROA (%) -6.47
CEMI's ROA (%) is ranked lower than
54% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. CEMI: -6.47 )
Ranked among companies with meaningful ROA (%) only.
CEMI' s 10-Year ROA (%) Range
Min: -53000  Med: -33.72 Max: 50.54
Current: -6.47
-53000
50.54
ROC (Joel Greenblatt) (%) -20.72
CEMI's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. CEMI: -20.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3093.62  Med: -18.12 Max: 98.41
Current: -20.72
-3093.62
98.41
Revenue Growth (3Y)(%) 8.50
CEMI's Revenue Growth (3Y)(%) is ranked higher than
65% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. CEMI: 8.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CEMI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -12.40 Max: 26.4
Current: 8.5
0
26.4
» CEMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CEMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 222.22
CEMI's Forward P/E is ranked lower than
97% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. CEMI: 222.22 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.54
CEMI's P/B is ranked higher than
63% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. CEMI: 2.54 )
Ranked among companies with meaningful P/B only.
CEMI' s 10-Year P/B Range
Min: 1.41  Med: 3.03 Max: 20.4
Current: 2.54
1.41
20.4
P/S 1.73
CEMI's P/S is ranked higher than
71% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. CEMI: 1.73 )
Ranked among companies with meaningful P/S only.
CEMI' s 10-Year P/S Range
Min: 0.19  Med: 1.26 Max: 5.01
Current: 1.73
0.19
5.01
Shiller P/E 21.95
CEMI's Shiller P/E is ranked higher than
70% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.91 vs. CEMI: 21.95 )
Ranked among companies with meaningful Shiller P/E only.
CEMI' s 10-Year Shiller P/E Range
Min: 13.17  Med: 17.30 Max: 22.57
Current: 21.95
13.17
22.57
Current Ratio 3.32
CEMI's Current Ratio is ranked higher than
58% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. CEMI: 3.32 )
Ranked among companies with meaningful Current Ratio only.
CEMI' s 10-Year Current Ratio Range
Min: 0.01  Med: 3.03 Max: 58
Current: 3.32
0.01
58
Quick Ratio 2.56
CEMI's Quick Ratio is ranked higher than
54% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. CEMI: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
CEMI' s 10-Year Quick Ratio Range
Min: 0.01  Med: 2.34 Max: 58
Current: 2.56
0.01
58
Days Inventory 82.37
CEMI's Days Inventory is ranked lower than
51% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. CEMI: 82.37 )
Ranked among companies with meaningful Days Inventory only.
CEMI' s 10-Year Days Inventory Range
Min: 37.8  Med: 73.11 Max: 87.12
Current: 82.37
37.8
87.12
Days Sales Outstanding 107.43
CEMI's Days Sales Outstanding is ranked lower than
82% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. CEMI: 107.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMI' s 10-Year Days Sales Outstanding Range
Min: 18.22  Med: 56.72 Max: 116.23
Current: 107.43
18.22
116.23

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.39
CEMI's Price/Net Current Asset Value is ranked higher than
71% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.30 vs. CEMI: 4.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMI' s 10-Year Price/Net Current Asset Value Range
Min: 2.2  Med: 5.86 Max: 37.33
Current: 4.39
2.2
37.33
Price/Tangible Book 2.66
CEMI's Price/Tangible Book is ranked higher than
72% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.26 vs. CEMI: 2.66 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMI' s 10-Year Price/Tangible Book Range
Min: 1.58  Med: 4.03 Max: 19.8
Current: 2.66
1.58
19.8
Price/Projected FCF 6.65
CEMI's Price/Projected FCF is ranked lower than
81% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. CEMI: 6.65 )
Ranked among companies with meaningful Price/Projected FCF only.
CEMI' s 10-Year Price/Projected FCF Range
Min: 1.49  Med: 3.80 Max: 14
Current: 6.65
1.49
14
Price/Median PS Value 1.40
CEMI's Price/Median PS Value is ranked lower than
73% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. CEMI: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMI' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.02 Max: 7.25
Current: 1.4
0.21
7.25
Earnings Yield (Greenblatt) (%) -4.42
CEMI's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. CEMI: -4.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.6  Med: 4.30 Max: 11.2
Current: -4.42
0.6
11.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Chembio Diagnostics Inc was formed in 1985. The Company with its subsidiaries develops, manufacture and market diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold under its STAT PAK, SURE CHECK or DPP registered trademarks. The Company's HIV tests are qualitative (reactive/non-reactive) tests. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.
» More Articles for CEMI

Headlines

Articles On GuruFocus.com
comment on CEMI Mar 06 2013 
comment on CEMI Mar 06 2013 

More From Other Websites
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 27 2015
Chembio to Host Conference Call to Discuss Second Quarter 2015 Financial Results Jul 27 2015
Chembio to Host Conference Call to Discuss Second Quarter 2015 Financial Results Jul 27 2015
First Quarter 10Q for Chembio Diagnostics, Inc. Jul 10 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 23 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 17 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 03 2015
Chembio's DPP(R) HIV 1/2 Assay Receives CE Mark Approval for Rapid Point-of-Care Detection of HIV Jun 03 2015
CHEMBIO DIAGNOSTICS, INC. Financials May 19 2015
CEMI: New Product Launches Should Steepen Revenue Curve May 12 2015
Chembio Diagnostics Reports First Quarter 2015 Financial Results May 07 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 07 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-Q, Quarterly Report May 07 2015
Q1 2015 Chembio Diagnostics Inc Earnings Release - Before Market Open May 07 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 01 2015
Chembio Launches HIV Self-Testing Initiative in Europe Apr 29 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Apr 28 2015
Chembio to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 27 2015
Chembio to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 27 2015
Chembio to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK